Home · Dosage Forms · Tablets · Capsules

Formulation & Development of Capsules.

Upperton is a leading contract development and manufacturing organisation (CDMO) with capabilities to develop across multiple dosage forms, including OSD Capsules. Speak to our experts about developing your molecule today.

Oral Dosage FOrms

Capsule Formulation Capabilities

Capsule formulations are often the favoured dosage form for initial clinical studies as they offer a fast, convenient way to deliver the API to the pharmacy. Capsules may contain simple unformulated API or more advanced formulations, such as amorphous spray-dried dispersions designed to enhance bioavailability.

Our Capsule Capabilities

We are able to work with capsule filling projects, taking programmes from early development through to GMP manufacturing.

10 GMP Manufacturing Rooms

350,000 Capsule filling capability per day

4,000 sq ft warehouse

500g-250kg blending capacity

100kg/hour Gerteis dry granulation capacity

20 litres Solution preparation vessels capacity with overhead mixing

Speak to us about your capsule needs.

Whether your project is early stage R&D or late stage manufacturing, speak to our team about how we can support your capsule needs.

Make an Enquiry

Oral Dosage Forms

Capsule Formulation Strategies

Filling spray dried powders and other API’s into hard shell HPMC or gelatin capsules enables projects to move more quickly into FIH or POC studies. In many cases, it is possible to fill capsules manually. As the trial progresses through the clinical stages. Scale up of batch size is managed through automation, into semi-automated capsules fillers (Profill range) and then onto fully automated capsule filling machines capable of producing several thousand capsules per hour. When developing the approach to capsule filling, consideration should be given to the target formulation, powder properties and the dose required.

Drugs that have short half-lives or are rapidly metabolized often require dosing three or four times a day to maintain drug levels in the required therapeutic range. In such cases, sustained-release dosage forms can reduce the frequency of dosing.